智通财经APP获悉，瑞银发布研报称，上调京东健康(06618)2025至2027年盈利预测4%至13%，并基于2027财年30倍市盈率或调整后盈利，将目标价从78.5港元上调至85港元;新目标价意味2027年1.25倍市盈增长率，维持“买入”评级。
瑞银称，京东健康今年第三季度在收入及利润均胜预期，收入同比增长从今年上半年的24.5%，加速至第三季度28.7%，认为主要由于药品销售的强劲增长、保健品业务增长显著回升，以及2024年第三季度基数相对较低。瑞银表示，考虑到京东健康药品增长维持强劲; 线上到线下(O2O)策略稳步推进，估计药品销售增长在今年第三季度维持约30%强劲增长，慢性病药及创新药增长更快。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.